key: cord-0954056-433j2yuz
authors: Kuno, Toshiki; So, Matsuo; Iwagami, Masao; Takahashi, Mai; Egorova, Natalia N.
title: The association of statins use with survival of patients with COVID-19()
date: 2021-12-22
journal: J Cardiol
DOI: 10.1016/j.jjcc.2021.12.012
sha: 07b913e7cad8e364400dbf893be5a50d447a223d
doc_id: 954056
cord_uid: 433j2yuz

BACKGROUND: Statins are frequently prescribed for patients with dyslipidemia and diabetes mellitus. These comorbidities are highly prevalent in coronavirus disease 2019 (COVID-19) patients. Statin's beneficial effect on mortality in COVID-19 infection has been reported in several studies. However, these findings are still inconclusive. METHODS: We conducted a retrospective observational study among 6,095 patients with laboratory confirmed COVID-19 hospitalized in Mount Sinai Health System between March 1st 2020 and May 7th 2020. Patients were stratified into two groups: statin use prior to or during hospitalization (N=2,423) versus no statins (N=3,672). We evaluated in-hospital mortality as a primary outcome using propensity score matching and inverse probability treatment weighted (IPTW) analysis. In additional analysis, we compared continuous use of statins (N=1,108) with no statins, continuous use of statins with discontinuation of statins (N=644), and discontinuation of statins with no statins. RESULTS: Among 6,095 COVID-19 patients, statin use prior to or during hospitalization group were older (70.8±12.7 years versus 59.2±18.2 years, p<0.001) and had more comorbidities compared to no statins group. After matching by propensity score (1,790 pairs), there were no significant differences in in-hospital mortality between patients with statins and those without [28.9% versus 31.0%, p=0.19, odds ratio (OR) 95% confidence interval (CI): 0.91 (0.79-1.05)]. This result was confirmed by IPTW analysis [OR (95% CI): 0.96 (0.81-1.12), p=0.53]. In the additional analysis comparing continuous use of statins with no statins group, in-hospital mortality was significantly lower in continuous use of statins compared to no statins group [26.3% versus 34.5%, p<0.001, OR (95% CI): 0.68 (0.55-0.82)] after matching by propensity score (944 pairs), as well as IPTW analysis [OR (95% CI): 0.77 (0.64-0.94), p=0.009]. Finally, comparison of continuous use of statins with discontinuation of statins showed lower in-hospital mortality in continuous use of statins group [27.9% versus 42.1%, p<0.001, OR (95% CI): 0.53 (0.41-0.68)]. CONCLUSIONS: Use of statins prior to or during hospitalization was not associated with a decreased risk of in-hospital mortality, however, continuous use of statins was associated with lower in-hospital mortality compared to no statin use and discontinuation of statins.

Tel: +1-718-920-2057 Fax +1-718-920-4321

This study was approved by the institutional review boards (#2000495) and conducted in accordance with the principles of the Declaration of Helsinki. The waiver of patients' informed consent was also approved by the institutional review boards.

In hospital mortality for patients who used statins prior to or during hospitalization group versus no statins group, antecedent use of statins group versus no statins group, continuous use of statins group versus no statins group, discontinuation of statins group versus no statins group, and discontinuation of statins group versus continuation of statins group reported the association of statin use with higher chance of asymptomatic infection, which also suggested the potential protective benefits of statins (6) ]. The effect of in-hospital use of statins by COVID-19 patients was reported to be favorable in preventing 28-day mortality in a retrospective study (7)]. In several other retrospective studies, the benefits of antecedent use of statins before admission were equivocal (8) (9) (10) (11) (12) (13) (14) ]. Moreover, despite the favorable results of using statin on survival in recent meta-analyses, the studies exposures included in these meta-analyses This study was approved by the institutional review boards (#2000495) and conducted in accordance with the principles of the Declaration of Helsinki. The waiver of patients' informed consent was also approved by the institutional review boards. Secondly, in the analysis of comparing antecedent use of statins group (statin use prior to hospitalization regardless of continuation or discontinuation of statins during hospitalization) (N=1,752) with no statins group (N=3,672) ( Fig. 1 ), antecedent use of statins group was older and more likely to have comorbidities compared to no statins group (Table 3) . Crude in-hospital outcomes are shown in Table 2 . In-hospital mortality was higher in the antecedent statins group than no statins group (32.3% versus 20.3%, p<0.001) ( Table 2 ). After propensity score matched analysis with well-balanced standardized mean differences <0.10 (1,329 pairs) ( In the analysis comparing continuous use of statins (statins use prior to and during hospitalization) (N=1,108) versus no statins group (N=3,672) ( Fig. 1) , continuous use of statins group was older and more likely to have comorbidities compared to no statins group (Table 4) .

Crude in-hospital outcomes are shown in Table 2 ).

In this study, almost 40% of patients were prescribed statins prior to or during the admissions due to COVID-19 infection and patients with antecedent use of statins were older and had more cardiovascular comorbidities, in line with previous studies (11, 13, 14) ]. The most important findings in our study are: 1) use of statins anytime either prior to or during hospitalization was not associated with lower in-hospital mortality compared to patients who did not receive statins; 2) statin use prior to admission alone did not demonstrate survival benefit compared to patients who were never on statins, however; 3) patients with continuous use of statins showed lower in-hospital mortality compared to patients who were never treated with statins; 4) among patients who were receiving statins prior to hospitalization, discontinuation of statins was associated with higher in-hospital mortality compared to continuous use of statins.

In a previous report, in-hospital use of statins were associated with 28-day mortality benefit in various models of statistical analyses, in which whether statins were antecedently prescribed was not clarified among the cohort (7)]. Some studies examined the effect of antecedent use of statins to COVID-19 showed in-hospital mortality benefit with no difference in secondary outcomes such as intensive care unit admission rate, mechanical ventilation rate, length of stay (11, 13, 14) ], while other studies showed no significant difference in mortality (8) (9) (10) 12) ]. In these studies, continuous use of statins during hospitalization was not clearly mentioned or investigated. The protective role of antecedent use of statins to prevent the occurrence of critically ill COVID-19 infection is still questionable given the result from previous reports, however.

We demonstrated that continuous use of statins (before and during hospitalization) was beneficial compared to the no statins and discontinuation of statins for patients with COVID-19. Interestingly, in-hospital mortality was even worse in the statins discontinuation group than in the no statins group. This effect can be attributable to statin rebound that leads to vascular dysfunction. This effect previously was described in animal studies (28)]. This result further strengthens the fact that discontinuation of statins is harmful to COVID-19 patients. Our study is not without limitations. Since this is an observational study, we could not adjust for unobserved confounders such as the severity of illness that may affect the ability to continue statins in patients with severe disease. The effect of severity of the illness on the decision to continue or discontinue statins could be considerable (36)].

Medication adherence before hospitalization was not taken into account in the study.

Prior history of coronary artery disease and cerebrovascular disease were not included as covariates.

Use of statins prior to or during hospitalization was not associated with a decreased risk of in-hospital mortality, however, continuous use of statins might have potential benefit of a decreased risk of in-hospital mortality due to COVID-19. 

Atorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/NF-kappaB signaling in PMA-stimulated THP-1 monocytes

National Heart, Lung, and Blood Institute ARDS Clinical Trials Network

Simvastatin in the acute respiratory distress syndrome

Statins and the COVID-19 main protease: in silico evidence on direct interaction

The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents

In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19

Statin use is associated with lower disease severity in COVID-19 infection

The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are needed

Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study

Statin Use and In-Hospital Mortality in Patients With Diabetes Mellitus and COVID-19

Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy

Beneficial Effect of Statins in COVID-19-Related Outcomes-Brief Report: A National Population-Based Cohort Study

Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19

Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients

Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis

The association of hemoglobin drop with in-hospital outcomes in COVID-19 patients

The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids

Prediction of in-hospital mortality with machine learning for COVID-19 patients treated with steroid and remdesivir

The association of COVID-19 antibody with in-hospital outcomes in COVID-19 infected patients

U shape association of hemoglobin level with in-hospital mortality for COVID-19 patients

The association between famotidine and in-hospital mortality of patients with COVID-19

The Association Between Convalescent Plasma Treatment and Survival of Patients with COVID-19

The Association of Inhaled Corticosteroid Before Admission and Survival of Patients with COVID-19

The characteristics and outcomes of critically Ill patients with COVID-19 who received systemic thrombolysis for presumed pulmonary embolism: an observational study

Creatinine, mg/dL (median

SD, standard deviation; SMD, standardized mean difference; IQR, interquartile range; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus